These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8014113)
1. Inhibition of topoisomerase II by a novel antitumor cyclic depsipeptide, BE-22179. Yoshinari T; Okada H; Yamada A; Uemura D; Oka H; Suda H; Okura A Jpn J Cancer Res; 1994 May; 85(5):550-5. PubMed ID: 8014113 [TBL] [Abstract][Full Text] [Related]
2. Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367. Yoshinari T; Mano E; Arakawa H; Kurama M; Iguchi T; Nakagawa S; Tanaka N; Okura A Jpn J Cancer Res; 1993 Jul; 84(7):800-6. PubMed ID: 8396568 [TBL] [Abstract][Full Text] [Related]
3. Determination of DNA topoisomerase II activity from L1210 cells--a target for screening antitumor agents. Wang LG; Liu XM; Ji XJ Zhongguo Yao Li Xue Bao; 1991 Mar; 12(2):108-14. PubMed ID: 1663690 [TBL] [Abstract][Full Text] [Related]
4. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Pommier Y; Covey JM; Kerrigan D; Markovits J; Pham R Nucleic Acids Res; 1987 Aug; 15(16):6713-31. PubMed ID: 2819825 [TBL] [Abstract][Full Text] [Related]
5. Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Pommier Y; Covey J; Kerrigan D; Mattes W; Markovits J; Kohn KW Biochem Pharmacol; 1987 Oct; 36(20):3477-86. PubMed ID: 2823823 [TBL] [Abstract][Full Text] [Related]
6. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II. Markovits J; Pommier Y; Mattern MR; Esnault C; Roques BP; Le Pecq JB; Kohn KW Cancer Res; 1986 Nov; 46(11):5821-6. PubMed ID: 3019538 [TBL] [Abstract][Full Text] [Related]
7. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973 [TBL] [Abstract][Full Text] [Related]
8. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Bowman KJ; Newell DR; Calvert AH; Curtin NJ Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322 [TBL] [Abstract][Full Text] [Related]
10. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Sullivan DM; Latham MD; Ross WE Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304 [TBL] [Abstract][Full Text] [Related]
12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
13. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434 [TBL] [Abstract][Full Text] [Related]
14. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage. Marx G; Zhou H; Graves DE; Osheroff N Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321 [TBL] [Abstract][Full Text] [Related]
15. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Holm B; Jensen PB; Sehested M Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793 [TBL] [Abstract][Full Text] [Related]
16. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Thielmann HW; Popanda O; Gersbach H; Gilberg F Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of topoisomerases by fredericamycin A. Latham MD; King CK; Gorycki P; Macdonald TL; Ross WE Cancer Chemother Pharmacol; 1989; 24(3):167-71. PubMed ID: 2544307 [TBL] [Abstract][Full Text] [Related]
18. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033 [TBL] [Abstract][Full Text] [Related]
19. A novel antitumor compound, NC-190, induces topoisomerase II-dependent DNA cleavage and DNA fragmentation. Yamagishi T; Nakaike S; Ikeda T; Ikeya H; Otomo S Cancer Chemother Pharmacol; 1996; 38(1):29-34. PubMed ID: 8603448 [TBL] [Abstract][Full Text] [Related]
20. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]